[ad_1]
“It is difficult at this point to accurately predict deadlines for vaccine authorization, as we do not yet have all the data and tests currently underway,” EMA said in an email sent to AFP news agency. .
“Depending on the progress of the evaluation, the EMA may indeed be able to complete the evaluation of the most advanced candidates later this year or early next,” the Agency said.
The EMA has established an accelerated procedure, which allows the safety and efficacy data of the vaccine to be examined as soon as they become available, even before a formal application for authorization is submitted by the manufacturers.
Vaccines from Oxford / AstraZeneca, Pfizer / BioNTech and Moderna are the three projects subject to this “ongoing review”.
Based in Amsterdam, the Netherlands, EMA’s mission is to authorize and control medicines in the European Union (EU).
The final go-ahead, given by the European Commission, allows laboratories to market their drugs across the EU.
This EMA statement comes after European Commission President Ursula von der Leyen said last week that the agency could approve the vaccines tested by Pfizer-BioNTech and Moderna “in the second half of December”.
British laboratory AstraZeneca, associated with the University of Oxford, announced Monday that it has developed a vaccine that is 70% effective on average, or up to 90% in some cases, based on interim results.
These results seem, for the time being, less convincing than those of its competitors from Pfizer / BioNTech or Moderna, whose efficacy exceeds 90%, but the British formula has the advantage of using more traditional technology, making your future vaccine less. expensive and easier to store.
Source link
